Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, AutologousTransplantation, HomologousHematopoietic Stem Cell MobilizationTransplantation ConditioningStem Cell TransplantationHematologic NeoplasmsGraft vs Host DiseaseLeukapheresisGranulocyte Colony-Stimulating FactorMelphalanAntigens, CD34Blood Component RemovalCombined Modality TherapyBone Marrow TransplantationGraft SurvivalCyclophosphamideHematopoietic Stem CellsBusulfanTreatment OutcomeMyeloablative AgonistsMultiple MyelomaStem CellsAntineoplastic Combined Chemotherapy ProtocolsCord Blood Stem Cell TransplantationTransplantation ChimeraRecurrenceTissue DonorsAntineoplastic Agents, AlkylatingRemission InductionLymphoma, Non-HodgkinEtoposideHistocompatibilityPOEMS SyndromeThiotepaWhole-Body IrradiationHistocompatibility TestingDisease-Free SurvivalInfectionTransplantation, IsogeneicRetrospective StudiesImmunosuppressive AgentsVidarabineAmyloidosisHematopoiesisSalvage TherapyLeukemiaSurvival RateIfosfamideSurvival AnalysisVincristineCarmustineBlood CellsGraft vs Leukemia EffectTime FactorsCytarabineHodgkin DiseaseLeukemia, Myeloid, AcutePlatelet CountMyelodysplastic SyndromesLymphomaCytomegalovirus InfectionsAnemia, AplasticNeoplasmsBlood Cell CountLiver TransplantationCytophagocytosisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFatal OutcomeLymphocyte DepletionFollow-Up StudiesFeasibility StudiesLivedo ReticularisHistiocytosis, Non-Langerhans-CellDoxorubicinOpportunistic InfectionsHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaCyclosporineHLA AntigensBone MarrowBlood DonorsImmunophenotypingImmunosuppressionRecombinant ProteinsProspective StudiesLymphoma, T-CellMesenchymal Stem Cell TransplantationPilot ProjectsBone Marrow PurgingPrednisoneCarboplatinPrognosisBone Marrow DiseasesAntineoplastic AgentsNeoplasm, ResidualAntigens, CDT-LymphocytesBlood Group Incompatibility